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Edited by Robert BaroukiAbstract Zinc-a2-glycoprotein (ZAG), a lipid mobilizing fac-
tor, is expressed in mouse adipose tissue and is markedly upreg-
ulated in mice with cancer cachexia. We have explored whether
ZAG is expressed and secreted by human adipocytes, using
SGBS cells, and examined the regulation of ZAG expression.
ZAG mRNA was detected by RT-PCR in mature human adipo-
cytes and in SGBS cells post-, but not pre-, diﬀerentiation to
adipocytes. Relative ZAG mRNA levels increased rapidly after
diﬀerentiation of SGBS cells, peaking at day 8 post-induction.
ZAG protein was evident in diﬀerentiated adipocytes (by day
3) and also detected in the culture medium (by day 6) post-induc-
tion. The PPARc agonist rosiglitazone induced a 3-fold increase
in ZAG mRNA level, while TNF-a led to a 4-fold decrease. Hu-
man adipocytes express and secrete ZAG, with ZAG expression
being regulated particularly through TNF-a and the PPARc nu-
clear receptor. ZAG is a novel adipokine, which may be involved
in the local regulation of adipose tissue function.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Zinc-a2-glycoprotein1. Introduction
Zinc-a2-glycoprotein (ZAG) is a 43 kDa soluble glycopro-
tein ﬁrst isolated from human plasma [1] and subsequently
found in secretory epithelia cells of liver, breast, the gastroin-
testinal tract, and sweat glands [2]. ZAG is overexpressed in
certain malignant tumors such that it may serve as a cancer
marker [3,4]. The biological functions of ZAG are largely un-
known, but it has been shown to act as a lipid-mobilizing fac-
tor [5,6]. Treatment with ZAG stimulates lipolysis in isolated
mouse and human adipocytes, and selectively reduces body
fat in both normal and ob/ob mice [6]. The lipolytic eﬀect of
ZAG in rodents has been attributed to the activation of b3-
adrenoreceptors and upregulation of cAMP [7].
White adipose tissue (WAT), conventionally considered sim-
ply as a site of fuel storage, is now recognized as a key endo-
crine organ [8–10]. It secretes a wide range of protein factors*Corresponding author. Fax: +44 151 706 5802.
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doi:10.1016/j.febslet.2004.11.042termed adipokines, including leptin, adiponectin, TNF-a, and
IL-6, which act locally and/or distantly in the regulation of en-
ergy balance and other physiological processes such as insulin
sensitivity and the inﬂammatory response. The secretory func-
tion of adipocytes, together with the lipolytic eﬀect of ZAG, led
us to consider that this protein might be produced directly by
WAT, and we have recently shown that ZAG is expressed by
mouse WAT as well as by murine 3T3-L1 adipocytes [11].
Moreover, ZAG mRNA and protein levels were increased sub-
stantially in WAT of mice bearing a cachexia-inducing tumor
that causes a profound loss of body weight and fat mass [11].
These ﬁndings suggest that adipocyte-derived ZAG may mod-
ulate adipose tissue metabolism locally. Interestingly, overex-
pression of ZAG in 3T3-L1 adipocytes has been reported to
lead to an increase in adiponectin mRNA levels [12].
Although ZAG appears to be expressed in WAT of obese
subjects [11], it is not known whether the protein is synthesized
in human adipocytes or whether it is secreted as an adipokine.
In this study, we have used the SGBS (Simpson-Golabi-Beh-
mel syndrome) cell strain to study ZAG synthesis in human
adipocytes; SGBS cells have a high capacity for diﬀerentiation
to mature cells that are functionally similar to human adipo-
cytes [13]. We demonstrate that human adipocytes express
the ZAG gene and that ZAG is secreted from SGBS cells. In
addition, we show that ZAG expression is regulated particu-
larly through the PPARc receptor and by TNF-a.2. Materials and methods
2.1. Human adipose tissue
Abdominal subcutaneous and omental adipose tissue were collected
during gastroplasty from six obese male patients, aged 35–48 years,
with body mass index >43; the subjects did not exhibit any other ongo-
ing disease. The study was approved by the Sefton Ethics Committee
and all patients gave their informed consent. After removal, samples
were immediately frozen in liquid nitrogen and stored at 80 C until
analysis.
2.2. Cell culture
SGBS cells were maintained and cultured as previously described
[13]. In brief, cells were cultured at 37 C in a humidiﬁed atmosphere
of 5% CO2/95% air. SGBS preadipocytes were maintained in DMEM/
Hams F12 (1:1) medium (Invitrogen) containing 10% (v/v) fetal calf
serum (FCS; Sigma) and antibiotics (penicillin/streptomycin). Diﬀeren-
tiation of the cells was initiated 24 h after conﬂuence by incubation for
4 days in FCS-free medium containing 0.25 lM dexamethasone, 500
lM 3-isobutyl-1-methyl-xanthine, 10 nM insulin, 200 pM triiodothy-blished by Elsevier B.V. All rights reserved.
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SmithKline). Diﬀerentiation into adipocytes was visualized under the
microscope from the accumulation of lipid droplets and by Oil Red
O staining. The cells were maintained in feeding medium (containing
insulin, cortisol and T3) for up to 25 days and collected every 1–3 days
in the case of the time course study of ZAG expression during diﬀer-
entiation, or for 10 days for studies on the regulation of ZAG expres-
sion. For the study on the secretion of ZAG during adipocyte
diﬀerentiation, culture medium was collected every 3 days; the medium
was centrifuged at 1000 rpm for 10 min and the supernatant stored at
20 C until analysis.
For studies on the regulation of ZAG expression, cells collected at
day 10 were pre-incubated for 24 h with cortisol-free feeding medium
or insulin-free feeding medium (for the study on the eﬀect of insulin).
Cells were then incubated for 24 h with medium containing each of the
following agents: noradrenaline (Fluka), BRL 37344 (Tocris), isopren-
aline, insulin, dexamethasone, TNF-a, interleukin-6 (IL-6), lipopoly-
saccharide (LPS) (Sigma), and rosiglitazone. The control cells for
each study were maintained in pre-incubation medium, which was re-
newed every 3 days. After completion of the treatment, cells were col-
lected in 700 ll of Trizol (Invitrogen).
Zen-Bio human preadipocytes and adipocytes diﬀerentiated in cul-
ture (Zen-Bio) were provided by Dr. Bohan Wang. cDNAs from ma-
ture adipocytes and stromal-vascular cells isolated by collagenase
digestion of human subcutaneous and omental adipose tissue were
provided by Dr. Stuart Wood.
2.3. RT-PCR
Total RNA was extracted from tissues (50–120 mg) and adipocytes
with Trizol. RNA samples used for real-time PCR were treated with a
DNA-free kit (Ambion) to remove any genomic DNA. The RNA con-
centration was determined from the absorbance at 260 nM. 1 lg of to-
tal RNA of each sample was reverse transcribed to cDNA in a ﬁnal
volume of 20 ll by using a Reverse-iT ﬁrst strand kit (ABgene). 1
ll of each cDNA sample was then ampliﬁed in a PCR mixture contain-
ing 0.02 mM of each primer and 1.1·Reddy Mix PCR Master Mix
(ABgene) in a ﬁnal volume of 25 ll. Human b-actin was used as a
housekeeping gene. The primer pair used and the PCR cycling condi-
tions were as follows.
Human ZAG (250-bp product): 5 0-CTT GGC TCA CTC AAT GAC
CT-3 0 (sense); 5 0-CTC CGC TGC TTC TGT TAT TC-3 0 (antisense);
annealing temperature (TA) 54 C; 33 cycles.
Human b-actin (281-bp product): 5 0-GTG GCA TCC ACG AAA
CTA CCT T-3 0 (sense); 5 0-GGA CTC GTC ATA CTC CTG CTT
G-3 0 (antisense); TA 57 C; 23 cycles.
Human leptin (422-bp product): 5 0-GAA CCC TGT GCG GAT TCT
TG-3 0 (sense); 5 0-CAC CTC TGT GGA GTA GCC TGA A-3 0 (anti-
sense); TA 56 C; 33 cycles.
Human adiponectin (352-bp product): 5 0-ATG CTG TTG CTG GGA
GCT GTT C-3 0 (sense); 5 0-CCA CAC TGA ATG CTG AGC GGT A-
3 0 (antisense); TA 60 C; 31 cycles.
PCR was performed on a thermal cycler (Hybaid) with an initial
denaturation at 94 C for 2 min followed by cycles consisting of dena-
turation at 94 C for 20 s, annealing at the speciﬁed temperature for 25
s, and extension at 72 C for 59 s; the ﬁnal step was an extension at 72
C for 5 min. PCR products were separated on a 1% agarose gel
stained with ethidium bromide. The PCR products were sequenced
commercially to conﬁrm their identity (MWG Biotech).2.4. Real-time PCR
Relative ZAG mRNA levels were quantiﬁed using real-time PCR
with an ABI Prism 7700 Sequence Detector (Applied Biosystems). Hu-
man b-actin mRNA levels were similarly measured and served as the
reference gene. Primers and Taqman probes were designed using Pri-
mer Express software (Applied Biosystems). The sequences of primers
and Taqman probes were as follows.
Human ZAG: 5 0-ACG ACA GTA ACG GGT CTC ACG TA-3 0 (for-
ward); 5 0-TCC TTT CCA TCA TAG TAA TAT TTC CAG AA-3 0 (re-
verse); 5 0-FAM-CAG GGA AGG TTT GGT TGT GAG ATC GAG
AAT AAC-TAMRA (probe).
Human adiponectin: 5 0-CCC AAA GAG GAG AGAGGA AGC T-30
(forward); 5 0-GCC AGA GCA ATG AGA TGC AA-3 0 (reverse); 5 0-
FAM-TTC CCA GAT GCC CCA GCA AGT GTA AC-TAMRA
(probe).Human IL-6: 5 0-GGT ACA TCC TCG ACG GCA TCT-3 0 (forward);
5 0-GTG CCT CTT TGC TGC TTT CAC-3 0 (reverse); 5 0-FAM-TGT
TAC TCT TGT TAC ATG TCT CCT TTC TCA GGG CT-TAMRA
(probe).
Human b-actin: 5 0-GGA TGC AGA AGG AGA TCA CTG-3 0 (for-
ward); 5 0-CGA TCC ACA CGG AGT ACT TG-3 0 (reverse); 5 0-
FAM-CCC TGG CAC CCA GCA CAA TG-TAMRA (probe).
Ampliﬁcation was performed in a 96-well plate using a master
mix made from qPCR core kit (Eurogentec), with 300 nM for-
ward (900 nM in the case of b-actin) and 900 nM reverse primers,
225 nM probe and 1 ll of cDNA in a ﬁnal volume of 25 ll. Each
sample was run in triplicate for ZAG and in duplicate for b-actin,
adiponectin, and IL-6. The PCR parameters were as follows: initial
2 min at 50 C, denaturation at 95 C for 10 min followed by 40
cycles of denaturation at 95 C for 15 s and combined annealing
and extension at 60 C for 1 min. Data were recorded and analyzed
with Sequence Detector software (Applied Biosystems). ZAG
mRNA levels were normalized to the values of b-actin and the re-
sults expressed as relative fold changes using the 2DDCt method
[14].2.5. Western blotting
Adipose tissue samples were homogenized in a buﬀer containing
250 mM sucrose, 1 mM N-2-hydroxyethylpiperazine-N 0-2-ethane-
sulfonic acid (HEPES), and 0.2 mM EDTA. The homogenate was
centrifuged at 12000 · g for 15 min at 4 C and the supernatant
containing soluble proteins collected. In the case of SGBS cells, Tri-
zol extraction for the isolation of proteins was performed according
to the manufacturers instructions. For the isolation of protein from
culture medium, samples of medium were incubated with 50% tri-
chloroacetic acid for 3 h on ice, followed by centrifugation at
12000g for 30 min at 4 C. The supernatant was discarded and
the protein pellet dissolved in 1% sodium dodecyl sulfate (SDS).
The protein concentration was determined using the bovine serum
albumin assay [15].
Samples containing 10–20 lg of protein were separated by SDS
gel-electrophoresis on 12% polyacrylamide gels. The proteins were
then transferred to nitrocellulose membranes (Hybond C; Amersham
Pharmacia) and immunoblotting performed overnight at 4 C. A
mouse monoclonal antibody to human ZAG (Santa Cruz Biotech-
nology) was employed at a 1:1000 dilution in Tris buﬀered saline
(pH 7.4) containing 0.1% Tween 20 and 5% dried milk. Blots were
then incubated for 1 h at room temperature with a rabbit anti-
mouse secondary antibody conjugated to horseradish peroxidase
(Santa Cruz Biotechnology) at a 1:1000 dilution. Signals were de-
tected by the enhanced chemiluminescence system (ECL; Amersham
Pharmacia).2.6. Statistical analysis
Data are presented as mean values ± S.E.M. Diﬀerences between
groups were analyzed by Students unpaired t test and were considered
to be statistically signiﬁcant when P < 0.05.3. Results
3.1. ZAG mRNA and protein in human WAT
In the initial experiments, the presence of ZAG mRNA in
human WAT, both subcutaneous and omental depots, was
conﬁrmed by RT-PCR (Fig. 1A), as in our previous work
[11]. Sequence analysis of the 250-bp product revealed 100%
homology with the corresponding region of human ZAG
cDNA. ZAG protein was also detected in both subcutaneous
and omental fat depots by Western blotting (Fig. 1B). RT-
PCR analysis of human subcutaneous and omental adipose tis-
sue fractionated by collagenase digestion indicated that the
ZAG gene was expressed primarily in mature adipocytes; a
weak signal was, however, also obtained with cells of the stro-
mal-vascular fraction (Fig. 1C).
Fig. 2. ZAG gene and protein expression during the diﬀerentiation
and development of SGBS cells to adipocytes. (A) ZAG, leptin and
adiponectin mRNA assessed by RT-PCR in SGBS cells; diﬀerentiation
was induced on day 0. (B) Relative ZAG mRNA levels (representative)
measured by real-time PCR in SGBS adipocytes. (C) Detection of
ZAG mRNA in human adipocytes (Zen-Bio) by RT-PCR at days 0
and 6 after the induction of diﬀerentiation. R, no RT control; T, no
template control.
Fig. 3. ZAG protein in SGBS adipocytes and ZAG release into the
culture medium. (A) Western blot of ZAG in SGBS cells before and
after the induction of diﬀerentiation. (B) Western blot of ZAG in the
culture medium of SGBS cells before and after the induction of
diﬀerentiation. Positive control, 10 ng of puriﬁed human ZAG protein.
Fig. 1. ZAG gene expression and ZAG protein in human adipose
tissue. (A) Detection of ZAG mRNA by RT-PCR in three individual
subjects (1–3). R, no RT control; T, no template control. (B)
Detection of ZAG protein in adipose tissue homogenates by Western
blotting. (C) ZAG mRNA detection by RT-PCR in human adipocytes
(Adip) and stromal-vascular cells (SV) isolated from omental and
subcutaneous fat depots by collagenase digestion. Sub, subcutaneous;
Om, omental.
Y. Bao et al. / FEBS Letters 579 (2005) 41–47 433.2. ZAG gene expression in SGBS adipocytes
SGBS cells in culture were employed to examine the expres-
sion of ZAG by human adipocytes. ZAG gene expression was
ﬁrst assessed by RT-PCR in SGBS cells before and after the
induction of diﬀerentiation to adipocytes. No signal for
ZAG mRNA was detected in the cells before induction (Fig.
2A); however, a signal was detected at day 1 post-induction
and thereafter (Fig. 2A). Expression of the adiponectin and
leptin genes was examined for comparison with ZAG, and
the mRNA for both these adipokine hormones was detected
in SGBS adipocytes post-diﬀerentiation, from days 2 and 5,
respectively (Fig. 2A).
To assess the quantitative changes in ZAG gene expres-
sion during the maturation of SGBS adipocytes, real-time
PCR was employed. ZAG mRNA levels increased gradually
from day 1 post-induction and reached a peak at day 8 of
>100 times that at day 2 (Fig. 2B). Further conﬁrmation
that ZAG mRNA occurs only in mature human adipocytes
was obtained from another human primary cell culture
system (Zen-Bio cells). Consistent with the results of SGBS
cells, no signal for ZAG mRNA was detected by RT-PCR
in these preadipocytes at day 0, while a clear signal
was present at day 6 after the induction of diﬀerentiation
(Fig. 2C).
3.3. ZAG protein expression and secretion by SGBS adipocytes
Western blotting was performed to establish whether ZAG
protein was present in SGBS adipocytes. During the time
course of the diﬀerentiation of SGBS cells to adipocytes,
ZAG protein was detected at day 3 post-induction and there-
after; no signal was obtained prior to this (Fig. 3A).
Western blotting was then performed on the culture medium
to determine whether ZAG is released by adipocytes. ZAG
protein was detected in the medium and as with the mRNAand protein measurements in the cells it was present only on
diﬀerentiation, with a faint signal appearing by day 6 post-
induction with a much stronger signal thereafter (Fig. 3B).
The signal for ZAG protein occurred at the same position as
the puriﬁed ZAG protein (from human serum; kindly provided
by Dr. ST Russell) (Fig. 3B).
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The regulation of ZAG gene expression in SBGS adipocytes
was investigated using real-time PCR to quantify the relative
ZAG mRNA levels. SGBS cells were treated at day 11 for
24 h with diﬀerent agents, at two dose levels. Treatment with
noradrenaline at either low or high doses had no eﬀect on
ZAG mRNA level (Fig. 4A). The addition of a selective b3-
adrenoceptor agonist, BRL 37344, led to a dose-dependent
increase in ZAG mRNA level, but this was only statistically
signiﬁcant (P < 0.001) with the higher dose which increased
the mRNA level 2.5-fold (Fig. 4B).0
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level (Fig. 4C). However, treatment with dexamethasone led
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fold increase being observed (Fig. 4D). The largest increase
in ZAG mRNA was observed with rosiglitazone, which re-
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doses (P < 0.001) (Fig. 5A). To assess the speciﬁcity of the
eﬀect of rosiglitazone on ZAG expression in SGBS adipo-
cytes, mRNA levels of two other adipokines, adiponectin,
and IL-6, were measured. Adiponectin mRNA level increased
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High dose). No reagent was added to the medium of control cells. Cells were pre-incubated for 24 h in dexamethasone-free medium before treatment:
Ros LD, 100 nM; Ros HD, 1lM; TNF LD, 1 ng/ml; and TNF HD, 50 ng/ml. ZAG, adiponectin and IL-6 mRNA levels, measured by real-time PCR,
are expressed relative to controls. Data are means ± S.E.M. for groups of 5–6. \P < 0.05, \\P < 0.01, and \\\P < 0.001, compared with controls.
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Fig. 5E).
Finally, the eﬀects on ZAG gene expression of the inﬂam-
mation-related agents, LPS, IL-6, and TNF-a were exam-
ined. LPS induced a very small (50%), albeit statistically
signiﬁcant (P < 0.05), increase in ZAG mRNA level (Fig.
4E). Addition of IL-6 did not aﬀect ZAG gene expression
(Fig. 4F). In contrast, TNF-a induced a dose-dependent
reduction in ZAG mRNA, the level decreasing 4-fold
(P < 0.001) with the higher dose (Fig. 5B). The eﬀect of
TNF-a on ZAG expression was compared with that on
adiponectin and IL-6. TNF-a induced a 10-fold reduction
(P < 0.001) in adiponectin mRNA at the higher dose (Fig.
5D); in contrast, IL-6 mRNA level was increased 5-fold
(P < 0.001) with the higher dose (Fig. 5F).4. Discussion
The present study demonstrates, using SGBS cells in cul-
ture, that ZAG is expressed by human adipocytes, ZAG
mRNA, and protein being present in diﬀerentiated adipocytes
but not in preadipocytes. ZAG mRNA was also evident in
freshly isolated human adipocytes, with only a very weak sig-
nal being found in cells of the stromal-vascular fraction
(which could reﬂect expression in any component of that
fraction, including macrophages and immature adipocytes).
In SGBS cells the signal for ZAG mRNA appeared from
day 1 after the induction of diﬀerentiation, with mRNA levels
rising rapidly and reaching a peak at day 8 post-induction.
ZAG protein was also detected in adipocytes at day 3 post-
induction and thereafter. The presence of ZAG mRNA and
46 Y. Bao et al. / FEBS Letters 579 (2005) 41–47protein shortly after the induction of diﬀerentiation implies
that ZAG is an early marker of diﬀerentiation in SGBS
adipocytes.
Importantly, the present study indicates that ZAG, which
contains a secretory signal sequence [4], is secreted by mature
adipocytes and is therefore a novel adipokine. ZAG was de-
tected in the medium from day 6 post diﬀerentiation, later than
it was detected in the adipocytes (day 3). This diﬀerence may re-
ﬂect a delay in the secretion ofZAG fromadipocytes, or the dilu-
tion of the protein by the medium such that detection is
compromised when the concentration is low; caution needs to
be exercised, however, in the interpretation since the measure-
ments ofZAGin the cells and themediumwerenotmade at iden-
tical timepoints. ZAG could in principle function locally within
WAT in an autocrine/paracrine manner, and/or contribute to
the circulating pool of the protein to act distantly as an endo-
crine signal. The previously observed lipolytic eﬀect of ZAG
on adipocytes [6], together with the greatly elevated expression
in WAT during the fat loss of cancer cachexia, suggests that
there may well be a major local autocrine/paracrine action.
The regulation of ZAG production in WAT is unknown,
although an initial study in 3T3-L1 adipocytes suggested that
at least in mice both dexamethasone and b3-adrenoceptor
agonists might be stimulatory [11]. The present study shows
that several factors inﬂuence ZAG gene expression in human
adipocytes. Although there was no eﬀect of noradrenaline,
some sympathetic involvement is suggested by the dose-depen-
dent increase in ZAG mRNA following treatment with the
b3-adrenoceptor agonist, BRL-37344. While this is similar to
previous observations with 3T3-L1 adipocytes [11], it is sur-
prising since the abundance of b3-adrenoceptors in adipose
tissue is much lower in humans than in rodents [16] and further
consideration may be needed.
Insulin had no signiﬁcant eﬀect on ZAG gene expression,
but a small increase in ZAG mRNA level was observed with
dexamethasone, suggesting some involvement of glucocorti-
coids consistent with 3T3-L1 adipocytes [11]. Dexamethasone
has been shown to strongly induce ZAG mRNA in human
breast cancer cells [17]. A very small stimulatory eﬀect was also
observed with the inﬂammatory agent LPS, although IL-6 had
no signiﬁcant eﬀect on ZAG gene expression.
The most substantial eﬀects on ZAG gene expression were
obtained with rosiglitazone and TNF-a. Treatment with rosig-
litazone, a selective PPARc agonist, induced a 3-fold increase
in ZAG mRNA level in SGBS cells, paralleling its eﬀect on
adiponectin mRNA, thus indicating that the PPARc nuclear
receptor is involved in the regulation of ZAG synthesis.
PPARc ligands have been implicated in the expression of sev-
eral adipokines, repressing those linked to insulin resistance as
well as the inﬂammatory response, such as resistin [18,19],
TNF-a [20,21], and PAI-1 [22]. In contrast, PPARc ligands
stimulate adiponectin, an insulin-sensitizing and anti-inﬂam-
matory adipokine [23,24], as also observed in this study.
Whether the stimulatory eﬀect of rosiglitazone on expression
implies a role for ZAG in insulin sensitivity or in mitigating
the inﬂammatory response in adipose tissue is not clear.
The largest eﬀect on ZAG synthesis was with the proinﬂam-
matory cytokine TNF-a. TNF-a led to a dose-dependent de-
crease in ZAG mRNA levels, with a 4-fold reduction at the
high dose, and this again paralleled the changes in adiponectin
mRNA. Several adipokines implicated in the inﬂammatory re-
sponse of adipose tissue, such as leptin, IL-6, MCP-1, andnerve growth factor, are substantially stimulated by TNF-a
in 3T3-L1 adipocytes [25–28]. Thus, the inhibitory eﬀect of
TNF-a on ZAG expression reported here suggests that ZAG
is unlikely to be part of the pro-inﬂammatory response of hu-
man adipocytes.
TNF-a is also considered to be a cachectic mediator, and it
has been shown to stimulate lipolysis in diﬀerentiated 3T3-L1
cells and human adipocytes [29–31]. Given that ZAG can func-
tion as a lipid-mobilizing factor, inhibition of ZAG expression
in adipocytes by TNF-a indicates that the two cachectic medi-
ators have diﬀerent eﬀects on lipid metabolism within adipose
tissue. It has been suggested that the lipolytic eﬀect of TNF-a
may be dependent on inhibition of the lipid-droplet associated
protein perilipin, since TNF-a-induced lipolysis in human
adipocytes parallels a decrease in perilipin synthesis [32]. In
contrast, the lipid-mobilizing eﬀect of ZAG has been attrib-
uted to the activation of b3-adrenoceptors and the cAMP path-
way in rodents [7], although it is unclear whether this is also
the case in humans.
TNF-a has been shown to inhibit adiponectin gene expression
in 3T3-L1 adipocytes [33] and in human adipose tissue in organ
culture [34]; as shown here, it also inhibits adiponectin expres-
sion in SGBS adipocytes. The inhibitory eﬀects of TNF-a to-
gether with the stimulatory eﬀect of rosiglitazone on ZAG
synthesis in adipocytes mirrors the regulation of adiponectin
by the two factors, which may point to a potential functional
link between the two adipokines. Indeed, it has been reported
that overexpression of ZAG in 3T3-L1 adipocytes leads to an in-
crease in adiponectin mRNA, raising the possibility that ZAG
might be a candidate gene in the regulation of body weight [12].
In conclusion, the work presented here demonstrates that hu-
man adipocytes express the ZAG gene and that ZAG protein is
secreted by diﬀerentiated adipocytes. The study also indicates
that both TNF-a and the PPARc nuclear receptor may be
important in the regulation of ZAG expression. ZAG appears
to be a novel adipokine, which may be involved in lipid metab-
olism and other processes in human adipose tissue.Acknowledgement: We are grateful for the assistance of Mrs. Laura
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